The Effect of Chinese Medicine Combined With Maximum Androgen Blockade on The Quality of Life of Patients with Advanced Prostate Cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033647

Enrollment

Unknown

Registered

2020-06-07

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

MAB group :goserellin + bicalutamide

CCM group:herbs + goserellin + bicalutamide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) accord with diagnostic criteria for advanced prostate cancer(clinical stage T2-4, n0-1, m0-1); (2) without any prostate cancer related treatment before diagnosis; (3) sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) infectious diseases such as hepatitis A, hepatitis B, and hepatitis C; (2) abdominal ultrasound showed obstructive diseases, and abdominal CT showed liver metastasis; (3) liver dysfunction; (4) serious cardiovascular and cerebrovascular diseases, renal insufficiency, and mental history; (5) primary malignant tumors other than prostate cancer.

Design outcomes

Primary

Measure	Time frame
The Quality of Life;	—

Secondary

Measure	Time frame
liver function;	—

Countries

China

Contacts

Public ContactYu Peng

Department of Urology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

drypeng@sina.com+86 18930568233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026